Total Payments
$268,259
2024 Payments
$35.28
Companies
17
Transactions
98
Medicare Patients
34,581
Medicare Billing
$986,132
Payment Breakdown by Category
Research$267,342 (99.7%)
Food & Beverage$884.45 (0.3%)
Education$32.27 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $267,342 | 38 | 99.7% |
| Food and Beverage | $884.45 | 59 | 0.3% |
| Education | $32.27 | 1 | 0.0% |
Payments by Type
Research
$267,342
38 transactions
General
$916.72
60 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $149,494 | 36 | $0 (2023) |
| Ascensia Diabetes Care US Inc. | $117,848 | 2 | $0 (2020) |
| Abbott Laboratories | $384.04 | 31 | $0 (2023) |
| Allergan, Inc. | $110.79 | 5 | $0 (2020) |
| Medtronic MiniMed, Inc. | $68.79 | 4 | $0 (2019) |
| Teva Pharmaceuticals USA, Inc. | $55.45 | 4 | $0 (2019) |
| Novo Nordisk Inc | $42.61 | 2 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $38.89 | 3 | $0 (2022) |
| Dexcom, Inc. | $38.48 | 1 | $0 (2022) |
| ABBVIE INC. | $36.24 | 2 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $35.28 | 2 | Eton Pharmaceuticals, Inc. ($18.67) |
| 2023 | $932.87 | 8 | Eli Lilly and Company ($837.84) |
| 2022 | $45,181 | 30 | Eli Lilly and Company ($44,967) |
| 2021 | $4,580 | 9 | Eli Lilly and Company ($4,485) |
| 2020 | $135,995 | 17 | Ascensia Diabetes Care US Inc. ($117,848) |
| 2019 | $3,230 | 8 | Eli Lilly and Company ($3,160) |
| 2018 | $53,030 | 13 | Eli Lilly and Company ($52,918) |
| 2017 | $25,275 | 11 | Eli Lilly and Company ($25,141) |
All Payment Transactions
98 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Curonix LLC | PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A (Device) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: PAIN MANAGEMENT | ||||||
| 08/01/2024 | Eton Pharmaceuticals, Inc. | ALKINDI (Drug) | Food and Beverage | Cash or cash equivalent | $18.67 | General |
| Category: Endocrinology | ||||||
| 11/08/2023 | Inspire Medical Systems, Inc. | INSPIRE (Device) | Food and Beverage | In-kind items and services | $33.10 | General |
| Category: NEUROLOGY | ||||||
| 07/11/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: Diabetes Care | ||||||
| 05/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $49.66 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | ||||||
| 04/13/2023 | PFIZER INC. | GENOTROPIN (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: ENDOCRINE DISEASE | ||||||
| 02/16/2023 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: Diabetes Care | ||||||
| 02/08/2023 | Eli Lilly and Company | — | — | In-kind items and services | $108.44 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $198.36 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | ||||||
| 01/10/2023 | Eli Lilly and Company | — | — | In-kind items and services | $481.38 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 12/22/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Diabetes Care | ||||||
| 11/27/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $14.40 | General |
| Category: Diabetes Care | ||||||
| 11/27/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $5.28 | General |
| Category: Diabetes Care | ||||||
| 11/09/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $4.48 | General |
| Category: Diabetes Care | ||||||
| 11/03/2022 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $38.48 | General |
| Category: Endocrinology | ||||||
| 10/03/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: Diabetes Care | ||||||
| 09/16/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $7.45 | General |
| Category: Diabetes Care | ||||||
| 08/24/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $13.08 | General |
| Category: Diabetes Care | ||||||
| 08/24/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $12.58 | General |
| Category: Diabetes Care | ||||||
| 08/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,105.00 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | ||||||
| 08/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $866.00 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 07/31/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $2.25 | General |
| Category: Diabetes Care | ||||||
| 07/30/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,584.00 | Research |
| Study: OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | ||||||
| 07/24/2022 | Eli Lilly and Company | — | — | In-kind items and services | $16,782.00 | Research |
| Study: A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | ||||||
| 07/18/2022 | Abbott Laboratories | FREESTYLE LIBRE (Device) | Food and Beverage | In-kind items and services | $2.08 | General |
| Category: Diabetes Care | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Clinical Trial Agreement - TV4 - GCA-PRO-2019-006-01 | Ascensia Diabetes Care US Inc. | $117,848 | 2 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO WITH AN OPEN-LABEL POSTPRANDIAL LY900014 TREATMENT GROUP, IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC, IN ADULTS WITH TYPE 1 DIABETES PRONTO-T1D | Eli Lilly and Company | $50,375 | 4 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND COMPARISON OF LY900014 TO INSULIN LISPRO, BOTH IN COMBINATION WITH INSULIN GLARGINE OR INSULIN DEGLUDEC IN ADULTS WITH TYPE 2 DIABETES PRONTO-T2D | Eli Lilly and Company | $18,217 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $16,782 | 1 |
| A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN GLARGINE IN ADULTS WITH TYPE 2 DIABETES ON MULTIPLE DAILY INJECTIONS | Eli Lilly and Company | $12,288 | 1 |
| A PHASE 2, RANDOMIZED, PARALLEL, OPEN-LABEL COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN STUDY PARTICIPANTS WITH TYPE 1 DIABETES MELLITUS PREVIOUSLY TREATED WITH MULTIPLE DAILY INJECTION THERAPY | Eli Lilly and Company | $9,900 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) | Eli Lilly and Company | $7,434 | 1 |
| A PROSPECTIVE, RANDOMIZED, DOUBLE BLIND COMPARISON OF LY900014 AND FIASP, BOTH IN COMBINATION WITH BASAL INSULIN IN ADULTS WITH TYPE 1 DIABETES PROTO COMPARE | Eli Lilly and Company | $6,550 | 2 |
| A PHASE 2 STUDY OF ONCE-DAILY LY3502970 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $3,412 | 1 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $3,343 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $3,235 | 2 |
| A STUDY OF LY3209590 IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $3,076 | 2 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $3,000 | 1 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $1,584 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $1,408 | 1 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA | Eli Lilly and Company | $1,347 | 2 |
| OBSTRUCTIVE SLEEP APNEA MASTER PROTOCOL GPIF: A STUDY OF TIRZEPATIDE (LY3298176) IN PARTICIPANTS WITH OBSTRUCTIVE SLEEP APNEA (SURMOUNT-OSA) | Eli Lilly and Company | $1,213 | 2 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $1,145 | 1 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $1,092 | 1 |
| A PHASE 2, PARALLEL, COMPARATOR CONTROLLED TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF LY3209590 IN INSULIN NAIVE PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $1,067 | 1 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $922.00 | 1 |
| A RANDOMIZED, PHASE 3, OPEN-LABEL TRIAL COMPARING THE EFFECT OF LY3298176 VERSUS TITRATED INSULIN DEGLUDEC ON GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $815.75 | 1 |
| THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) | Eli Lilly and Company | $551.70 | 1 |
| A STUDY OF LY900014 IN PARTICIPANTS WITH TYPE 2 DIABETES USING CONTINUOUS GLUCOSE MONITORING | Eli Lilly and Company | $359.38 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITH TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-2) | Eli Lilly and Company | $198.36 | 1 |
| RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN | Eli Lilly and Company | $128.00 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO FOR MAINTENANCE OF WEIGHT LOSS IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-4) | Eli Lilly and Company | $49.66 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 32 | 4,725 | 5,185 | $363,053 | $94,732 |
| 2022 | 53 | 9,293 | 13,334 | $895,768 | $272,713 |
| 2021 | 54 | 9,874 | 14,413 | $952,860 | $299,373 |
| 2020 | 58 | 10,689 | 17,122 | $1.1M | $319,314 |
Total Patients
34,581
Total Services
50,054
Medicare Billing
$986,132
Procedure Codes
197
All Medicare Procedures & Services
197 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 521 | 563 | $129,490 | $34,563 | 26.7% |
| 83970 | Parathormone (parathyroid hormone) level | Office | 2023 | 212 | 225 | $25,875 | $9,067 | 35.0% |
| 82306 | Vitamin d-3 level | Office | 2023 | 211 | 224 | $19,040 | $6,451 | 33.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 565 | 671 | $8,052 | $5,600 | 69.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 462 | 496 | $26,288 | $5,109 | 19.4% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 477 | 519 | $21,279 | $4,903 | 23.0% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 329 | 337 | $19,209 | $4,401 | 22.9% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 223 | 240 | $13,200 | $3,950 | 29.9% |
| 85027 | Complete blood cell count (red cells, white blood cell, platelets), automated test | Office | 2023 | 463 | 500 | $17,500 | $3,155 | 18.0% |
| 84481 | Thyroid hormone, t3 measurement, free | Office | 2023 | 134 | 144 | $7,920 | $2,377 | 30.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 45 | $7,425 | $1,746 | 23.5% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 242 | 247 | $11,362 | $1,394 | 12.3% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 147 | 156 | $8,580 | $1,372 | 16.0% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 249 | 255 | $6,120 | $1,291 | 21.1% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 81 | 92 | $5,152 | $1,229 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $4,500 | $1,064 | 23.7% |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | Office | 2023 | 48 | 48 | $3,936 | $908.16 | 23.1% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 26 | 26 | $4,810 | $888.75 | 18.5% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 11 | 11 | $715.00 | $700.70 | 98.0% |
| 84432 | Thyroglobulin (thyroid related hormone) level | Office | 2023 | 39 | 40 | $3,800 | $617.07 | 16.2% |
| 86800 | Thyroglobulin (thyroid protein) antibody measurement | Office | 2023 | 39 | 40 | $3,200 | $611.19 | 19.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 17 | 17 | $2,295 | $514.18 | 22.4% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 24 | 24 | $1,836 | $432.48 | 23.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 48 | $2,251 | $412.21 | 18.3% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 15 | 75 | $3,000 | $352.70 | 11.8% |
About Dr. Carl Vance, MD
Dr. Carl Vance, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Idaho Falls, Idaho. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1437159423.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Carl Vance, MD has received a total of $268,259 in payments from pharmaceutical and medical device companies, with $35.28 received in 2024. These payments were reported across 98 transactions from 17 companies. The most common payment nature is "" ($267,342).
As a Medicare-enrolled provider, Vance has provided services to 34,581 Medicare beneficiaries, totaling 50,054 services with total Medicare billing of $986,132. Data is available for 4 years (2020–2023), covering 197 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Idaho Falls, ID
- Active Since 07/30/2005
- Last Updated 10/15/2021
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1437159423
Products in Payments
- FREESTYLE LIBRE (Device) $134.96
- FreeStyle Libre (Device) $120.80
- Minimed 670G System (Device) $68.79
- AJOVY (Drug) $55.45
- FreeStyle Libre Pro (Device) $49.42
- UBRELVY (Drug) $47.28
- FREESTYLE LIBRE 3 (Device) $44.35
- Kerendia (Drug) $38.89
- Dexcom G6 Transmitter (Medical Supply) $38.48
- FreeStyle Libre blood glucose Flash Monitoring System (Device) $34.51
- INSPIRE (Device) $33.10
- VRAYLAR (Drug) $24.98
- BROVANA (Drug) $23.87
- SYNTHROID (Drug) $21.43
- BYSTOLIC (Drug) $19.76
- Increlex (Drug) $19.13
- VIBERZI (Drug) $18.77
- ALKINDI (Drug) $18.67
- GENOTROPIN (Drug) $17.58
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A (Device) $16.61
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.